13 February 2020
Linnéa Schmidt has received 50,000 DKK from the Harboe Foundation for the project ”Exploring actionable stratifications of B-cell cancer patients using CRISPR/Cas9 genetic screening”. The study aims at identifying treatment resistance genes in the B-cell malignancy diffuse large B cell lymphoma (DLBCL) for the current second-line and/or experimental drugs cisplatin, carboplatin, bendamustin, bortezomib and iphosphamid using a global CRISPR/Cas9 screening approach.